Ruth M RisueÃ±o

List of Publications by Year
in descending order

39	3,487	471509 17	414414 32
papers	citations	h-index	g-index

40	40	40	5518
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lysosome-mediated chemoresistance in acute myeloid leukemia. Cancer Drug Resistance (Alhambra,) Tj ETQq1 1 0.784314 rgBT /Overlo	2.1	2
2	Natural killer cells efficiently target multiple myeloma clonogenic tumor cells. Cancer Immunology, Immunotherapy, 2021, 70, 2911-2924.	4.2	6
3	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 662 Td	9.1	1,430
4	Histamine receptor 1 is expressed in leukaemic cells and affects differentiation sensitivity. Journal of Cellular and Molecular Medicine, 2020, 24, 13536-13541.	3.6	1
5	Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes. Scientific Reports, 2020, 10, 18927.	3.3	6
6	Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells. EBioMedicine, 2019, 47, 221-234.	6.1	19
7	Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML. Scientific Reports, 2018, 8, 13883.	3.3	11
8	Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target. Leukemia, 2017, 31, 2288-2302.	7.2	20
9	Sam68 Allows Selective Targeting of Human Cancer Stem Cells. Cell Chemical Biology, 2017, 24, 833-844.e9.	5.2	38
10	Repositioning of bromocriptine for treatment of acute myeloid leukemia. Journal of Translational Medicine, 2016, 14, 261.	4.4	18
11	Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells. Oncotarget, 2016, 7, 23239-23250.	1.8	13
12	Biological and Therapeutic Implications of Cancer Stem Cells. , 2016, , 63-101.		0
13	Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. Cancer Cell International, 2015, 15, 122.	4.1	4
14	G-CSF Reduces ex vivo Acute Myeloid Leukemia Blasts Cells Viability in the Presence of Bone Marrow Stroma Cells. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S189-S190.	0.4	0
15	The lincRNA<i>HOTAIRM1</i>, located in the<i>HOXA</i>genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Oncotarget, 2015, 6, 31613-31627.	1.8	78
16	Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. Blood, 2015, 126, 2511-2511.	1.4	0
17	High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome. Leukemia Research, 2014, 38, 874-881.	0.8	16
18	XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. Oncotarget, 2014, 5, 4337-4346.	1.8	20

#	Article	IF	Citations
19	Autologous Activated and Expanded Natural Killer Cells Kill Clonogenic Myeloma Cells: A New Therapeutic Option for Multiple Myeloma. Blood, 2014, 124, 3467-3467.	1.4	0
20	The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. Blood, 2014, 124, 1003-1003.	1.4	0
21	DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1, FLT3-ITD and CEBPA. Blood, 2013, 122, 1339-1339.	1.4	0
22	BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. Blood, 2013, 122, 2577-2577.	1.4	0
23	Inability of Human Induced Pluripotent Stem Cell-Hematopoietic Derivatives to Downregulate MicroRNAs In Vivo Reveals a Block in Xenograft Hematopoietic Regeneration. Stem Cells, 2012, 30, 131-139.	3.2	33
24	Identification of Drugs IncludingÂa DopamineÂReceptor Antagonist that Selectively Target Cancer Stem Cells. Cell, 2012, 149, 1284-1297.	28.9	420
25	Identification of T-lymphocytic leukemiaâ€"initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood, 2011, 117, 7112-7120.	1.4	21
26	Brief Report: Ectopic Expression of Nup98-HoxA10 Augments Erythroid Differentiation of Human Embryonic Stem Cells. Stem Cells, 2011, 29, 736-741.	3.2	4
27	Direct conversion of human fibroblasts to multilineage blood progenitors. Nature, 2010, 468, 521-526.	27.8	652
28	Cooperativity Between T Cell Receptor Complexes Revealed by Conformational Mutants of CD3É›. Science Signaling, 2009, 2, ra43.	3.6	90
29	T Cell Receptor Engagement Triggers Its CD3Îµ and CD3Î¶ Subunits to Adopt a Compact, Locked Conformation. PLoS ONE, 2008, 3, e1747.	2.5	30
30	Differential antibody binding to the surface ÂÂTCR{middle dot}CD3 complex of CD4+ and CD8+ T lymphocytes is conserved in mammals and associated with differential glycosylation. International Immunology, 2008, 20, 1247-1258.	4.0	16
31	Targeting LSCs: powering an old tool. Blood, 2008, 111, 5423-5424.	1.4	1
32	Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects. Current Opinion in Hematology, 2008, 15, 319-325.	2.5	49
33	Conformational Model. Advances in Experimental Medicine and Biology, 2008, 640, 103-112.	1.6	6
34	The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers. Clinical and Experimental Immunology, 2007, 150, 375-385.	2.6	17
35	A conformation- and avidity-based proofreading mechanism for the TCRâ€"CD3 complex. Trends in Immunology, 2006, 27, 176-182.	6.8	65
36	A conformational change senses the strength of T cell receptor-ligand interaction during thymic selection. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9625-9630.	7.1	37

#	Article	IF	Citations
37	Ligand-induced conformational change in the T-cell receptor associated with productive immune synapses. Blood, 2005, 106, 601-608.	1.4	74
38	Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. Journal of Experimental Medicine, 2005, 202, 493-503.	8.5	288
39	New Therapeutic Approaches for Acute Myeloid Leukaemia. European Medical Journal (Chelmsford,) Tj ETQq1 1 0.784314 rgBT /Overl	3.0	1